FT Options’s ProQR Therapeutics PRQR Stock Holding History

FT Options’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-12,523	Closed	-$61K	–	436
2016 Q2	$61K	Hold	12,523	–	–	0.05%	188
2016 Q1	$61K	Buy	+12,523	New	+$63.7K	0.06%	151

Other funds holding PRQR

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

HCMT

Highland Capital Management (Texas) Dallas, Texas $39M AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AGA

Altrinsic Global Advisors Stamford, Connecticut $2.79B AUM 7.25% 1-Year Est. Return

FT Options's PRQR Position: Q3 2016 in Review

FT Options sold out of ProQR Therapeutics (PRQR) in Q3 2016, closing a stake of 12,523 shares — an estimated $61K sold.

FT Options first reported a position in PRQR in Q1 2016 and held it in 2 quarters. The position peaked at $61K in Q2 2016. 25 funds tracked by Wall St. Rank hold PRQR as of Q3 2016.

FT Options reported no remaining ProQR Therapeutics position as of Q3 2016 after selling out during the quarter.
FT Options sold 12,523 ProQR Therapeutics shares in Q3 2016, an estimated $61K.
FT Options first reported a position in ProQR Therapeutics in Q1 2016 and held it in 2 quarters.
FT Options's ProQR Therapeutics position peaked at $61K in Q2 2016.
25 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q3 2016.

Based on FT Options's 13F filing for Q3 2016, filed 10 Nov 2016.